



Jersey

MISUSE OF DRUGS (GENERAL PROVISIONS) (AMENDMENT) (JERSEY) ORDER 2009

Made

16th November 2009

Coming into force

23rd November 2009

THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 13 and 27 of the Misuse of Drugs (Jersey) Law 1978¹, orders as follows –

1 Interpretation

In this Order “principal Order” means the Misuse of Drugs (General Provisions) (Jersey) Order 2009².

2 Schedule 1 substituted

For Schedule 1 to the principal Order there shall be substituted the following Schedule –

“SCHEDULE 1

(Article 1)

SCHEDULE 1 DRUGS

1 The following substances and products –

- (a) Amphetamine
- Bufotenine
- Cannabinol
- Cannabinol derivatives except dronabinol and except any stereo-isomer of dronabinol
- Cannabis and cannabis resin
- Cathinone

Coca leaf
Concentrate of poppy-straw
Eticyclidine
Etryptamine
Gammahydroxybutyrate
Lysergamide
Lysergide and other N-alkyl derivatives of lysergamide
Mescaline
Methcathinone
Methylamphetamine
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy- α -methylphenethylamine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
2,5-Dimethoxy- α , 4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex;

(b) any compound (not being a compound specified in subparagraph (a)) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c) the following phenethylamine derivatives –

Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo- β ,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy- α -methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[β]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[β]furan-6-yl)-1-methylethylamine
 β -Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(α -Methyl-3,4-methylenedioxyphenethylamino)ethanol
 α -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 α -Methyl-4-(methylthio)phenethylamine
 $\beta,3,4,5$ -Tetramethoxyphenethylamine
 $\beta,2,5$ -Trimethoxy-4-methylphenethylamine;

- (d) any compound (not being methoxyphenamine or a compound specified in sub-paragraph (a)) structurally derived from phenethylamine, an N-alkylphenethylamine, α methylphenethylamine, an N-alkyl- α -methylphenethylamine, α -ethylphenethylamine, or an N-alkyl- α -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways –

-
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle,
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups,
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups,
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups,
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxy carbonyl or alkoxyalkyl or acyloxy group,
 - (vi) by replacement of the N-propionyl group by another acyl group;
- (f) any compound (not being a compound specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways –
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted,
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted,
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups,
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group,
 - (v) by formation of an N-oxide or of a quaternary base;
- (g) 1-benzylpiperazine;
- (h) any compound structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in either of the following ways –
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl substituents,
 - (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl substituents;
- (i) 3,4-methylenedioxy methcathinone (Mephedrone);
- (j) 3-keto-3,4-methylbenzodioxylbutanamine (Butylone);
- (k) 4-methylmethcathinone (Mephedrone);
- (l) any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-
-

- morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- (m) any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- (n) any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- (o) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent;
- (p) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent.
- 2 Any stereoisomeric form of a substance specified in paragraph 1.
- 3 Any ester or ether of a substance specified in paragraph 1 or paragraph 2.
- 4 Any salt of a substance specified in any of paragraphs 1 to 3.
- 5 Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 not being a preparation specified in Schedule 5.”.

3 Schedule 2 substituted

For Schedule 2 to the principal Order there shall be substituted the following Schedule –

“SCHEDULE 2

(Article 1)

SCHEDULE 2 DRUGS

- 1 The following substances and products –

Acetorphine
Alfentanil
Allylprodine
Alphacetylmethadol
Alphameprodine
Alphamethadol
Alphaprodine
Anileridine
Benzethidine
Benzylmorphine (3-benzylmorphine)
Betacetylmethadol
Betameprodine
Betamethadol
Betaprodine
Bezitramide
Carfentanil
Clonitazene
Cocaine
4-Cyano-2-dimethylamino-4,4-diphenylbutane
4-Cyano-1-methyl-4-phenylpiperidine
Desomorphine
Dextromoramide
Diamorphine
Diampromide
Diethylthiambutene
Difenoxin
Dihydrocodeinone O-carboxymethyloxime
Dihydroetorphine
Dihydromorphine
Dimenoxadole
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl butyrate
Diphenoxylate
Dipipanone

Dronabinol
Drotebanol
Ecgonine and any derivative of ecgonine which is convertible to ecgonine or to cocaine
Ethylmethylthiambutene
Etonitazene
Etorphine
Etoxeridine
Fentanyl
Furethidine
Hydrocodone
Hydromorphinol
Hydromorphone
Hydroxypethidine
Isomethadone
Ketobemidone
Levomethorphan
Levomoramide
Levophenacymorphan
Levorphanol
Lofentanil
Medicinal opium
Metazocine
Methadone
Methadyl acetate
Methyldesorphine
Methyldihydromorphine,(6-methyldihydromorphine)
1-Methyl-4-phenylpiperidine-4-carboxylic acid
2-Methyl-3-morpholino-1,1-diphenylpropanecarboxylic acid
 α -Methylphenethylhydroxylamine
Metopon
Morpheridine
Morphine
Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

Myrophine
Nicomorphine
Noracymethadol
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Oxycodone
Oxymorphone
Pethidine
Phenadoxone
Phenampramide
Phenazocine
Phencyclidine
Phenomorphane
Phenoperidine
4-Phenylpiperidine-4-carboxylic acid ethyl ester
Piminodine
Piritramide
Proheptazine
Properidine
Racemethorphan
Racemoramide
Racemorphan
Remifentanyl
Sufentanyl
Thebacon
Thebaine
Tilidate
Trimeperidine
Zipeprol.

- 2 Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.
- 3 Any ester or ether of a substance specified in paragraph 1 or paragraph 2, not being a substance specified in paragraph 6.
- 4 Any salt of a substance specified in any of paragraphs 1 to 3.

-
- 5 Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
- 6 The following substances and products –
- Acetyldihydrocodeine
 - Buprenorphine
 - Codeine
 - Dextropropoxyphene
 - Diethylpropion
 - Dihydrocodeine
 - Ethylmorphine (3-ethylmorphine)
 - Fenethylamine
 - Glutethimide
 - Lefetamine
 - Mecloqualone
 - Methaqualone
 - Methylphenidate
 - Nicocodine
 - Nicodicodine (6-nicotinoyldihydrocodeine)
 - Norcodeine
 - Pentazocine
 - Phenmetrazine
 - Phentermine
 - Pholcodine
 - Propiram
 - Quinalbarbitone.
- 7 Any stereoisomeric form of a substance specified in paragraph 6.
- 8 Any salt of a substance specified in paragraph 6 or paragraph 7.
- 9 Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.”

4 Citation and commencement

This Order may be cited as the Misuse of Drugs (General Provisions) (Amendment) (Jersey) Order 2009 and shall come into force 7 days after it is made.

DEPUTY A.E. PRYKE OF TRINITY

Minister for Health and Social Services

¹ *chapter 08.680*
² *R&O.23/2009*